SER

Serina Therapeutics Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↑ 7/10
  • Momentum↓ 0/10
Serina Therapeutics sales and earnings growth
SER Growth
Good
  • Revenue Y/Y↓ -96.33%
  • EPS Y/Y↑ 55.37%
  • FCF Y/Y↓ -32.45%
Serina Therapeutics gross and profit margin trends
SER Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -16022.40%
  • ROIC↑ 6493.10%
Serina Therapeutics net debt vs free cash flow
SER Risk
Great
  • Debt / Equity↓ 1.9
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -579.8

Serina Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗